Equillium (NYSE:EQ) Downgraded by Zacks Investment Research
According to Zacks, “Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company’s product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. “
Separately, HC Wainwright set a $10.00 price objective on Jaguar Health and gave the stock a buy rating in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Equillium has an average rating of Buy and a consensus target price of $17.75.
Equillium (NYSE:EQ) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04).
Institutional investors have recently bought and sold shares of the business. American International Group Inc. bought a new position in Equillium during the 4th quarter worth $28,000. Deutsche Bank AG bought a new position in Equillium during the 4th quarter worth $54,000. Partner Investment Management L.P. bought a new position in Equillium during the 4th quarter worth $64,000. Geode Capital Management LLC bought a new position in Equillium during the 4th quarter worth $143,000. Finally, Northern Trust Corp bought a new position in Equillium during the 4th quarter worth $298,000.
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
See Also: Quiet Period Expirations Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.